Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 10/20 | 0.39 |
| ▸ | WHR1 | P49842 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17721515 | 0.98 | CCNE2 (0.40) | ADORA3VCPWHR1GBA1PIM1 | |
| SCHEMBL17721541 | 0.91 | KDM4E (0.41) | VCPPIM1 | |
| SCHEMBL17721550 | 0.91 | ROCK2 (0.35) | ADORA3VCPPIM1HTR4 | |
| SCHEMBL17721565 | 0.91 | VCP (0.39) | ADORA3VCPPIM1HTR4GRIN2B | |
| SCHEMBL17721578 | 0.90 | VCP (0.40) | VCPPIM1GRIN2B | |
| SCHEMBL17721540 | 0.89 | CYP11B2 (0.43) | VCPWHR1PIM1HTR4 | |
| SCHEMBL17721610 | 0.89 | IDH1 (0.46) | VCPPIM1HTR4 | |
| SCHEMBL17721514 | 0.89 | GRIN2B (0.38) | VCPPIM1HTR4GRIN2B | |
| SCHEMBL16928071 | 0.88 | VCP (0.41) | ADORA3VCPGRIN2B | |
| SCHEMBL17721521 | 0.88 | PIM1 (0.34) | ADORA3VCPPIM1HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970153-B1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | THE US SECRETARY OF THE ARMY ON BEHALF OF WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2018-02-21 | — | — | EP | claimed |
| US-9334246-B2 | Substituted triazines for malaria treatment and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2016-05-10 | — | — | US | claimed |
| EP-3351538-A1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | The United States of America, as represented by The Secretary of The Army, on behalf of Walter Reed Army Institute of Research (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-2970153-B1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | THE US SECRETARY OF THE ARMY ON BEHALF OF WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9700562-B2 | Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160213675-A1 | Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis | WALTER REED ARMY INST OF RES THE USA AS REPRESENTED BY THE SEC OF THE ARMY ON BEHALF OF THE (US) | 2016-07-28 | — | — | US | disclosed |
| US-9334246-B2 | Substituted triazines for malaria treatment and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150210652-A1 | Substituted Triazines for Malaria Treatment and Chemoprophylaxis | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210652-A1 | Substituted Triazines for Malaria Treatment and Chemoprophylaxis | CYP3A5, HCCS, COX15 | ADORA3 2985/4885VCP 4612/4885WHR1 4411/4885 |
| US-20160213675-A1 | Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis | HCCS, CYP3A5, COX15 | ADORA3 2845/4885VCP 4687/4885WHR1 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.